Unit:
Speciality Cardiometabolic MedicineLibrary of the School of Health Sciences
Supervisors info:
Κασσή Ευανθία, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Λαμπαδιάρη Βαϊα, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Οικονόμου Ευάγγελος, Επίκουρος καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
-Omics technologies for profiling metabolic changes of hepatocytes in different stages of NAFLD
Translated title:
-Omics technologies for profiling metabolic changes of hepatocytes in different stages of NAFLD
Summary:
Non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most prevalent liver disorder globally, linked to diabetes, obesity and cardiovascular risks. Understanding its progression, from simple steatosis to cirrhosis and hepatocellular carcinoma (HCC), is crucial for patient management and treatment strategies. The disease's complexity requires innovative approaches for early detection and personalized care.
Omics technologies—such as genomics, transcriptomics, proteomics and metabolomics—are revolutionizing the study of NAFLD/MASLD. These high-throughput techniques allow for a deeper exploration of the molecular mechanisms driving disease progression. Genomics can identify genetic predispositions, while transcriptomics and proteomics reveal changes in gene expression and protein profiles during disease evolution. Metabolomics offers insights into the metabolic alterations associated with NAFLD/MASLD, potentially identifying novel biomarkers for early diagnosis and disease monitoring.
By integrating data from various omics platforms, researchers can map out the intricate biochemical pathways involved in liver disease progression. This holistic approach not only enhances our understanding of NAFLD/MASLD but also paves the way for non-invasive diagnostic tools and targeted therapies. As omics technologies continue to advance, they hold the promise of transforming NAFLD/MASLD management, leading to more precise and effective interventions that can mitigate the burden of this widespread liver disease.
Main subject category:
Health Sciences
Keywords:
Metabolic dysfunction-associated fatty liver disease (MAFLD), Metabolic dysfunction-associated steatotic liver disease (MASLD), Non-alcoholic fatty liver disease (NAFLD), -Omics Technologies, Genomics, Transcriptomics, Proteomics, Metabolomics, Biomarkers, Metabolism, Hepatocytes
Number of references:
241
File:
File access is restricted until 2025-12-04.
Bourganou Maria MSc.pdf
805 KB
File access is restricted until 2025-12-04.
